



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 27, 2014 March 14, 2018

VECAMYL™ (mecamylamine)

LENGTH OF AUTHORIZATION: Up to six months

INITIAL REVIEW CRITERIA

Hypertension:

- Diagnosis of moderately severe to severe hypertension AND
- Use of at least 6 other classes of antihypertensives medications within the last 12 months with documented history of failure to achieve blood pressure goals using maximum tolerated doses AND
- Prescriber must verify patient does **NOT** have any of the following conditions:
 - Coronary insufficiency
 - Recent myocardial infarction
 - Rising/elevated BUN or renal insufficiency
 - Uremia
 - Patient receiving concomitant antibiotics or sulfonamides
 - Glaucoma
 - Organic pyloric stenosis
 - Hypersensitivity to mecamylamine

CONTINUATION OF THERAPY

- Must have recent claims history (within previous 3 months) for Vecamyl and continue to meet criteria listed for initial therapy

DOSING & ADMINISTRATION:

- The average total daily dose of mecamylamine for the treatment of hypertension is 25 mg, usually given in three divided doses but dose should be individualized based on blood pressure response and individual patient tolerance.
- Dosage Form: 2.5 mg tablets